Other than skin cancer, prostate cancer affects more men in the U.S. than any other cancer, and nearly 30,000 men in the U.S. die of prostate cancer each year. It strikes a staggering one in six men and—until now—transrectal ultrasound biopsies performed in a systematic fashion (rather than aiming at target) have been the standard of care once cancer of the prostate is suspected. However, these systematic biopsies miss 20-30% of cancers, and many cancers that are detected may not be clinically significant
Artemis gives your urologist the technology to navigate to a desired location for prostate biopsy and record this information for future reference, treatment planning and monitoring. This breakthrough in imaging and mapping is a major improvement over existing 2D ultrasound routinely used for prostate cancer biopsies. Without being able to clearly see the prostate in real-time, urologists have had no choice but to gather less-than-precise information to determine treatment. When targeting a biopsy, your physician can navigate throughout the prostate gland with a much higher degree of accuracy and confidence. Thus you can be assured of a better diagnosis of possible cancer.
Your physician can provide you with a detailed report showing your prostate dimensions, biopsy sites, and where cancer or other anomalies may be found. If you are on an active surveillance plan, your subsequent biopsies will be much more accurately sampled. This is because your physician now has the ability to re-biopsy the same location in the gland or to sample other areas around any specific biopsy location.